401 related articles for article (PubMed ID: 21439354)
1. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs?
Schüle C; Eser D; Baghai TC; Nothdurfter C; Kessler JS; Rupprecht R
Neuroscience; 2011 Sep; 191():55-77. PubMed ID: 21439354
[TBL] [Abstract][Full Text] [Related]
2. The role of allopregnanolone in depression and anxiety.
Schüle C; Nothdurfter C; Rupprecht R
Prog Neurobiol; 2014 Feb; 113():79-87. PubMed ID: 24215796
[TBL] [Abstract][Full Text] [Related]
3. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity.
Schüle C; Romeo E; Uzunov DP; Eser D; di Michele F; Baghai TC; Pasini A; Schwarz M; Kempter H; Rupprecht R
Mol Psychiatry; 2006 Mar; 11(3):261-72. PubMed ID: 16344854
[TBL] [Abstract][Full Text] [Related]
4. Neuroactive steroids in depression and anxiety disorders: clinical studies.
Eser D; Schüle C; Baghai TC; Romeo E; Rupprecht R
Neuroendocrinology; 2006; 84(4):244-54. PubMed ID: 17159334
[TBL] [Abstract][Full Text] [Related]
5. Neuroactive steroids as modulators of depression and anxiety.
Eser D; Romeo E; Baghai TC; di Michele F; Schüle C; Pasini A; Zwanzger P; Padberg F; Rupprecht R
Neuroscience; 2006; 138(3):1041-8. PubMed ID: 16310959
[TBL] [Abstract][Full Text] [Related]
6. Neuroactive steroids and affective disorders.
Eser D; Schüle C; Baghai TC; Romeo E; Uzunov DP; Rupprecht R
Pharmacol Biochem Behav; 2006 Aug; 84(4):656-66. PubMed ID: 16831459
[TBL] [Abstract][Full Text] [Related]
7. Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients.
Schüle C; Baghai TC; di Michele F; Eser D; Pasini A; Schwarz M; Rupprecht R; Romeo E
Psychoneuroendocrinology; 2007 Jul; 32(6):669-80. PubMed ID: 17560730
[TBL] [Abstract][Full Text] [Related]
8. Neurosteroids and neuroactive drugs in mental disorders.
Pisu MG; Serra M
Life Sci; 2004 May; 74(26):3181-97. PubMed ID: 15094320
[TBL] [Abstract][Full Text] [Related]
9. Neuroactive steroids: mechanisms of action and neuropsychopharmacological properties.
Rupprecht R
Psychoneuroendocrinology; 2003 Feb; 28(2):139-68. PubMed ID: 12510009
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression.
Baghai TC; di Michele F; Schüle C; Eser D; Zwanzger P; Pasini A; Romeo E; Rupprecht R
Neuropsychopharmacology; 2005 Jun; 30(6):1181-6. PubMed ID: 15702138
[TBL] [Abstract][Full Text] [Related]
11. Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile.
Nothdurfter C; Rammes G; Baghai TC; Schüle C; Schumacher M; Papadopoulos V; Rupprecht R
J Neuroendocrinol; 2012 Jan; 24(1):82-92. PubMed ID: 21609361
[TBL] [Abstract][Full Text] [Related]
12. Differential modulation of the gamma-aminobutyric acid type C receptor by neuroactive steroids.
Morris KD; Moorefield CN; Amin J
Mol Pharmacol; 1999 Oct; 56(4):752-9. PubMed ID: 10496958
[TBL] [Abstract][Full Text] [Related]
13. Neuroactive steroids and fatigue severity in patients with primary biliary cirrhosis and hepatitis C.
Ahboucha S; Butterworth RF; Pomier-Layrargues G; Vincent C; Hassoun Z; Baker GB
Neurogastroenterol Motil; 2008 Jun; 20(6):671-9. PubMed ID: 18282171
[TBL] [Abstract][Full Text] [Related]
14. Partial agonism by 3alpha,21-dihydroxy-5beta-pregnan-20-one at the gamma-aminobutyric acidA receptor neurosteroid site.
Xue BG; Whittemore ER; Park CH; Woodward RM; Lan NC; Gee KW
J Pharmacol Exp Ther; 1997 Jun; 281(3):1095-101. PubMed ID: 9190841
[TBL] [Abstract][Full Text] [Related]
15. Neuroactive steroids as endogenous modulators of anxiety.
Eser D; Baghai TC; Schüle C; Nothdurfter C; Rupprecht R
Curr Pharm Des; 2008; 14(33):3525-33. PubMed ID: 19075729
[TBL] [Abstract][Full Text] [Related]
16. Neuroactive steroids and GABAA receptor plasticity in the brain of the WAG/Rij rat, a model of absence epilepsy.
Pisu MG; Mostallino MC; Dore R; Mura ML; Maciocco E; Russo E; De Sarro G; Serra M
J Neurochem; 2008 Sep; 106(6):2502-14. PubMed ID: 18624910
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO).
Nothdurfter C; Rupprecht R; Rammes G
Curr Top Med Chem; 2012; 12(4):360-70. PubMed ID: 22204486
[TBL] [Abstract][Full Text] [Related]
18. Social isolation stress-induced aggression in mice: a model to study the pharmacology of neurosteroidogenesis.
Matsumoto K; Pinna G; Puia G; Guidotti A; Costa E
Stress; 2005 Jun; 8(2):85-93. PubMed ID: 16019600
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like and anxiolytic-like effects of YL-IPA08, a potent ligand for the translocator protein (18 kDa).
Zhang LM; Zhao N; Guo WZ; Jin ZL; Qiu ZK; Chen HX; Xue R; Zhang YZ; Yang RF; Li YF
Neuropharmacology; 2014 Jun; 81():116-25. PubMed ID: 24067925
[TBL] [Abstract][Full Text] [Related]
20. Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action.
Uzunova V; Sampson L; Uzunov DP
Psychopharmacology (Berl); 2006 Jun; 186(3):351-61. PubMed ID: 16249906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
